SkinBioTherapeutics PLC Enrolment for AxisBiotix-Ps(TM) study commences (4707L)
January 13 2021 - 1:00AM
UK Regulatory
TIDMSBTX
RNS Number : 4707L
SkinBioTherapeutics PLC
13 January 2021
13 January 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Enrolment for AxisBiotix-Ps(TM) food supplement consumer study
commences
-- Enrolment commenced for the AxisBiotix-Ps(TM) food supplement consumer study
-- Targeting 200+ applicants, study will be monitored through a smart phone application
-- Study due to commence in February 2021
SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces that AxisBiotix Limited, a wholly
owned subsidiary of the Company, has commenced enrolment for its
food supplement consumer study.
AxisBiotix-Ps (TM) food supplement consumer study
Further to research exploring the relationship between the gut
and the skin and the scientific evidence pointing to a link between
gut dysfunction, stress-induced alterations to the gut microbiome
and skin inflammation, the Company has been working with Winclove
Probiotics B.V. ("Winclove") for the development of a blend of
bacterial strains as a food supplement.
A proprietary blend of bacterial strains has been specifically
designed to balance the gut microbiome to address the over
production of new skin cells often seen in aggressive skin
conditions such as psoriasis. Psoriasis is a debilitating skin
condition caused by a malfunction of the immune system whereby
raised 'plaques' form on the skin, which can be flaky, scaly and
itchy. There is currently no cure for psoriasis; therapies tend to
be steroid-based, which cannot be used long term and have side
effects. The condition is common, with approximately 2% of the
global population believed to suffer from psoriasis.
With Winclove having completed formulation and manufacture of
the supplement, and unable to initiate its clinic based human study
due to the Covid-19 restrictions, the Company has established a
protocol for a 'self-managed' food supplement study.
The study, which will accept approximately 200 applicants, is
now open for enrolment through the website www.axisbiotix.com . The
participants will be asked to take a powdered food supplement
dissolved in a glass of water on a daily basis and the study will
run for a total of 56 days (2 x 28-day blocks). Thereafter the data
will be collated and analysed to assess the impact the supplement
has had on the health of the skin. The study is monitored through a
mobile phone application with frequent questions for participants
and the submission of photographs of affected areas taken using
their smart devices. As such the study is not impacted by current
COVID restrictions.
The supplements have been manufactured by Winclove and are
currently being packaged ahead of shipment to the Company in early
February. The supplements will then be dispatched to the study
participants with an expected start date before the end of February
2021. The study will conclude before the end of April 2021 and the
Company expects to be able to report on the study findings shortly
thereafter. Subject to a positive outcome, the Company will then
target a commercial launch of the product during the course of 2021
and in parallel initiate a clinic based study looking at specific
markers.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"2020 was a year of transition for SkinBioTherapeutics with a
focus on flexibility. We managed a smooth evolution from research
into development, and proactively managed our way around the ever
changing obstacles that the global pandemic presented and continues
to present.
"The preparatory work carried out last year has ensured that we
remain on track with all our strategic and commercial goals as we
move into 2021, where we expect to see significant progress across
several of our strategic channels. The launch of the AxisBiotix
(TM) website and the recruitment of candidates for our
AxisBiotix-Ps(TM) study, as well as the ongoing progress made by
Sederma with our skin care programme, heralds the start of our
commercialisation drive."
-Ends-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFFFLTIFLIL
(END) Dow Jones Newswires
January 13, 2021 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024